I confirm that I work for Angion Biomedica and that I have been given the task by its management to manage this profile.
I will keep all information up to date and agree to receive notifications related to job posts, discussions, and any other content related to the company.

Cancel 

Company Name:
Company Url:
Short Pitch:
Description:
Headquarter Location:
Tags:

Job Url:
  •  Url

  •  

  •  

  •  

  •  
  •   

  •  Event 

  • Last Edited: 2021-06-04 08:50:27

  • Last User:  james

Angion Biomedica


Angion is a clinical stage biopharmaceutical company focused on acute kidney injury, a potentially life-threatening condition without therapeutic options. Our lead clinical asset, ANG-3777, is engineered to activate the HGF/c-MET pathway, an important mechanism in organ repair. Angion is developing ANG-3777 to meet the high unmet medical need of acute kidney injury resulting from kidney transplantation and from cardiac surgery. We are currently conducting Phase 2 and Phase 3 clinical trials with improvement in kidney function as an endpoint. Angion’s robust pipeline includes ANG-3070, an oral small molecule in development as a potential treatment for fibrosis and other severe organ damage.

Headquarter Location:
Uniondale, New York